| Literature DB >> 28918410 |
Nikita Berman1,2, Melvyn Mark Jones1, Daan A De Coster3.
Abstract
OBJECTIVE: The objective of the study was to investigate the symptoms people with diabetes experience when having a myocardial infarction (MI), their illness narrative and how they present their symptoms to the health service.Entities:
Keywords: chest pain; myocardial infarction
Mesh:
Year: 2017 PMID: 28918410 PMCID: PMC5640147 DOI: 10.1136/bmjopen-2016-015736
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Description of participants
| Participant | Age range (years) | Type of DM | Duration of DM range (years) | Treatment of DM | Type of MI |
| 1 | 70–79 | 2 | 10–19 | OHG | NSTEMI |
| 2 | 50–59 | 2 | 10–19 | OHG/In | NSTEMI |
| 3 | 80–89 | 2 | 10–19 | OHG/In | Acute MI unspecified |
| 4 | 40–49 | 2 | 0–9 | OHG | NSTEMI |
| 5 | 70–79 | 2 | 20–29 | OHG | NSTEMI |
| 6 | 50–59 | 2 | 10–19 | In | NSTEMI |
| 8 | 70–79 | 2 | 10–19 | OHG | Acute MI unspecified |
| 10 | 70–79 | 2 | 10–19 | OHG/diet | STEMI |
| 11 | 50–59 | 1 | 10–19 | In | STEMI |
| 13 | 60–69 | 2 | NR | OHG/In | NSTEMI |
| 14 | 80–89 | 2 | 0–9 | OHG | STEMI |
| 15 | 60–69 | 2 | 0–9 | OHG | STEMI |
| 16 | 70–79 | 2 | 0–9 | OHG | NSTEMI |
| 17 | 60–69 | 2 | >10 | OHG+ | NSTEMI |
| 18 | 70–79 | 2 | NR | Acute MI unspecified | |
| 19 | 60–69 | 1 | 40–49 | In | NSTEMI |
| 20 | 80–89 | 2 | 0–9 | OHG | NSTEMI |
| 21 | 70–79 | 2 | >10 | OHG | Acute MI unspecified/cardiac arrest |
| 22 | 60–69 | 2 | NR | OHG | NSTEMI |
| 23 | 60–69 | 2 | 0–9 | OHG | Acute MI unspecified/cardiac arrest |
| 24 | 70–79 | 2 | 10–19 | OHG | NSTEMI/cardiac arrest |
| 25 | 70–79 | 2 | >25 | OHG/In | STEMI |
| 26 | 50–59 | 2 | 10–19 | OHG/In | STEMI |
| 27 | 70–79 | 2 | 0–9 | OHG | STEMI/cardiac arrest |
| 29 | 50–59 | 1 | 30–39 | In | NSTEMI |
| 30 | 60–69 | 2 | 10–19 | OHG+/In | NSTEMI |
| 31 | 40–49 | 2 | 0–9 | OHG | STEMI |
| 32 | 80–89 | 2 | >20 | OHG+ | NSTEMI |
| 33 | 60–69 | 2 | 10–19 | OHG+ | STEMI |
| 34 | 60–69 | 2 | 10–19 | OHG | STEMI |
| 35 | 50–59 | 2 | 0–9 | Diet | NSTEMI |
| 36 | 40–49 | 2 | 20–29 | OHG/In | NSTEMI |
| 37 | 60–69 | 2 | 0–9 | NSTEMI | |
| 38 | 70–79 | 2 | 10–19 | OHG | NSTEMI |
| 39 | 50–59 | 2 | 10–19 | OHG/In | NSTEMI |
| 40 | 40–49 | 1 | 30–39 | OHG/In | NSTEMI |
| 41 | 90–99 | 2 | 30–39 | In | NSTEMI |
| 42 | 50–59 | 2 | 0–10 | OHG | NSTEMI |
| 43 | 60–69 | 2 | 10–19 | OHG | NSTEMI |
Cases 7, 9, 12 and 28 are not included as they did not meet study criteria.
Treatment key: OHG, oral hypoglycaemics (eg, metformin/glicazide and so on); In, insulins; OHG+, oral hypoglycaemics+other drugs, for example, gliptins/glitazones.
DM, diabetes mellitus; MI, myocardial infarction; NSTEMI, non-ST elevated MI; STEMI, ST elevated MI.
Figure 1How diabetes (grey boxes) might affect the ‘health belief model’ during MI. (adapted from Strecher and Rosenstock.48). DM, diabetes mellitus; IHD, ischaemic heart disease; MI, myocardial infarction.